-
公开(公告)号：US20240270865A1
公开(公告)日：2024-08-15
申请号：US18020955
申请日：2021-08-06
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , CARINE PATUREL , IVAN PERROT
IPC: C07K16/28 , A61K31/337 , A61K39/00 , A61P35/00 , C07K16/32
CPC classification number: C07K16/2896 , A61K31/337 , A61P35/00 , C07K16/32 , A61K2039/507 , A61K2039/545 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/76
Abstract: The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods for administering anti-CD73 antibodies, and to methods for using anti-CD73 antibodies for the treatment of cancers, preferably HER2-positive gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma in an individual.
-
公开(公告)号：US20240124579A1
公开(公告)日：2024-04-18
申请号：US18396776
申请日：2023-12-27
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , SIMON KOLLNBERGER , BENJAMIN ROSSI , HÉLÈNE SICARD , CARINE PATUREL , STÉPHANIE CORNEN , STÉPHANIE ZERBIB
IPC: C07K16/28 , G01N33/569
CPC classification number: C07K16/2803 , G01N33/56966 , G01N33/56972 , A61K2039/505 , G01N2800/7095
Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
-
公开(公告)号：US20210340254A1
公开(公告)日：2021-11-04
申请号：US17376314
申请日：2021-07-15
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NICOLAS SCHNEIDER
Abstract: The present invention provides antibodies having improved stability. Included are antibodies that are capable of binding to KIR3DL2 polypeptides. The antibodies are suitable for the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sezary Syndrome, and KIR3DL2-expressing autoimmune disorders.
-
公开(公告)号：US20180355036A1
公开(公告)日：2018-12-13
申请号：US16066688
申请日：2016-12-20
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NADIA ANCERIZ , ARIANE MOREL , BENJAMIN ROSSI
CPC classification number: C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K16/468 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/526 , C07K2317/622 , C07K2317/732 , C07K2317/92
Abstract: NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
-
公开(公告)号：US20150291692A1
公开(公告)日：2015-10-15
申请号：US14429416
申请日：2013-09-17
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , BENJAMIN ROSSI , HÉLÈNE SICARD , CARINE PATUREL
IPC: C07K16/28 , G01N33/569 , A61K47/48
CPC classification number: C07K16/2803 , A61K47/6803 , A61K47/6849 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/565 , C07K2317/732 , C07K2317/734 , C07K2317/77 , C07K2317/92 , G01N33/56972 , G01N2333/70503 , G01N2800/24 , G01N2800/52 , G01N2800/7028 , G01N2800/7095
Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy, to a method of selecting an appropriate chemotherapeutic treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one of a soluble B7H6 (sB7H6 or sB7-H6) and a soluble MIC (sMIC) and when the expression level is determined a step b) of comparing said expression level to a reference expression level, thereby assessing or monitoring whether the subject having a tumor is responsive or resistant to the chemotherapy.
Abstract translation: 本发明涉及一种预测或监测具有肿瘤的受试者对化疗的敏感性的方法，选择适合的癌症化学治疗的方法，筛选或鉴定适于改善治疗的化合物的方法 癌症，以及相应的药盒。 预测或监测具有肿瘤的受试者对化疗的敏感性的方法通常包括以下步骤：a）在来自所述受试者的生物样品中测定可溶性B7H6中的至少一种的存在，不存在或表达水平（ sB7H6或sB7-H6）和可溶性MIC（sMIC），并且当确定表达水平时，将所述表达水平与参考表达水平进行比较的步骤b），从而评估或监测具有肿瘤的受试者是否具有反应性或抗性 化疗。
-
Patent Agency Ranking
公开(公告)号：US20150232556A1
公开(公告)日：2015-08-20
申请号：US14662349
申请日：2015-03-19
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , SIMON KOLLNBERGER , BENJAMIN ROSSI , HÉLÈNE SICARD , CARINE PATUREL , STÉPHANIE CORNEN , STÉPHANIE ZERBIB
IPC: C07K16/28 , G01N33/569
Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
Abstract translation: 本发明涉及使用特异性结合KIR3DL2的抗体（例如单克隆抗体），抗体片段及其衍生物来治疗癌症和炎性疾病的方法。 本发明还涉及抗体，产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 含有该组合物的药物组合物。
-
公开(公告)号：US20240174748A1
公开(公告)日：2024-05-30
申请号：US18432126
申请日：2024-02-05
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NADIA ANCERIZ , ARIANE MOREL , BENJAMIN ROSSI
CPC classification number: C07K16/2803 , C07K16/2809 , C07K16/2887 , C07K16/468 , C12N5/10 , C12N15/00 , C12N15/64 , C12N15/66 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/526 , C07K2317/622 , C07K2317/732 , C07K2317/92 , C12N2511/00 , C12N2523/00
Abstract: The application pertains to NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
-
公开(公告)号：US20210269523A1
公开(公告)日：2021-09-02
申请号：US17315547
申请日：2021-05-10
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , NADIA ANCERIZ , ARIANE MOREL , BENJAMIN ROSSI
Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
-
公开(公告)号：US20200023071A1
公开(公告)日：2020-01-23
申请号：US16483758
申请日：2018-02-05
Applicant: INNATE PHARMA
Inventor： MATHIEU BLERY , DELPHINE BREGEON , LAURENT GAUTHIER , FLORENCE LHOSPICE , LAURENT POUYET
IPC: A61K47/68 , C07K16/28 , A61P35/00 , A61K31/551 , A61K38/07
Abstract: The present invention provides antigen-binding proteins capable of binding to human MICA polypeptides, conjugated to cytotoxic agents. Said conjugates have increased activity in the treatment of disorders characterized by MICA-expressing cells, particularly tumor cells.
-
公开(公告)号：US20190071514A1
公开(公告)日：2019-03-07
申请号：US16084249
申请日：2017-03-14
Applicant: INNATE PHARMA , OREGA BIOTECH
Inventor： LAURENT GAUTHIER , CARINE PATUREL , IVAN PERROT
IPC: C07K16/28 , A61P35/00 , G01N33/574
Abstract: The present invention relates to antigen-binding compounds that inhibit CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g. cancer.
-
-
-
-
-
-
-
-
-
Search Results
25
records
(took 0.027 seconds)
